BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Antengene Clears U.S. IND for Phase I Trial of ATG-031 Antibody

- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody to advance to the clinic in oncolog...

May 18, 2023 | News

Sirnaomics to Receive HK$8M Subsidy for Clinical Translational Catalyst Plan

The subsidy comes under HKSTP's Clinical Translational Catalyst ("CTC") programme dedicated to catalysing clinical translation to bring innovative, life-ch...

May 18, 2023 | News

Boan Biotech's BA1202 Approved for Clinical Trial

Boan Biotech announced today that its BA1202, a CEACAM5 (CEA)/CD3 bispecific antibody, has been approved for a clinical trial by the Center for Drug Evalua...

May 17, 2023 | News

Antengene Announces NDA Submission for XPOVIO® in Indonesia

"In just six months, we have submitted NDAs for XPOVIO® in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting...

May 17, 2023 | News

Crystal Formulation Services' GMP facility passes remote US audit, marks global expansion milestone.

The audit was focused to confirm that the GMP manufacturing facility of CFS meets the US GMP regulations, and to ensure the compliance in manufacturing and...

May 15, 2023 | News

Novavax's COVID-Influenza Combo and High-dose COVID Vaccine Show Strong Immune Responses in Phase 2

This Phase 2 trial is evaluating three vaccine candidates: COVID-Influenza Combination, stand-alone influenza and high-dose COVID Preliminary topline im...

May 10, 2023 | News

Ascletis approved for Phase IIa clinical trial of ASC10 for RSV infection in China

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Do...

May 09, 2023 | News

Bliss Biopharmaceutical Collaborates with Eisai for Clinical Trial of BB-1701 with Strategic Option

This collaboration with Eisai is an important advancement in BlissBio's corporate development plan to further develop BB-1701 globally and help advance BB-...

May 08, 2023 | News

EirGenix's Breast Cancer Biosimilar EG1206A Meets Phase 1 Trial Goals

Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show that the main test indicators have met the pharmacokinetics...

May 08, 2023 | News

Cambridge Infinitus Research Centre Launches AI-based ERnet Platform for Cellular Health Studies.

With an impact factor of 47.99, Nature Methods is the world's leading international publication for biochemical research methodology. Upon public...

May 05, 2023 | News

ABM Initiates Phase I Clinical Trial of MEK Inhibitor for Solid Tumor, Doses First Patient

MEK (mitogen-activated protein kinase kinase), a key kinase of the MAPK pathway, is frequently activated in various cancers, including those with RAS mutat...

May 05, 2023 | News

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform

Nous-209 has been developed using the Nouscom's viral vector platform, which includes adenoviral and Modified Vaccinia Ankara (MVA) vectors, with MVA vecto...

May 04, 2023 | News

Revolutionizing Drug Development: IQVIA's David Cameron on the Power of Innovative Trial Designs

Can you tell us about your role as Senior Director & Global Head of Novel Trial Design at IQVIA? The Novel Trial Design initiative at IQ...

May 09, 2023 | News

The Impact of Digital Health Technologies in Oncology: Current State and Future Directions

Digital health has revolutionized the way healthcare is delivered and managed in recent years. Oncology is one field that has benefited significantly from ...

May 03, 2023 | Opinion

Stay Connected